Retrospective cohort study assesses immunity to vaccines in pediatric leukemia survivors, suggesting need for revaccination.
Key Points
Assess serologic immunity to measles, mumps, rubella, and varicella among pediatric leukemia survivors and identify determinants of immune persistence.
Retrospective cohort study of 192 pediatric leukemia survivors treated with non-HSCT chemotherapy from 2021 to 2023.
Serologic testing for IgG antibodies against measles, mumps, rubella, and varicella.
Logistic regression analysis of associations between patient characteristics and serologic immunity.
Overall seropositivity: 37.0% for measles, 40.6% for mumps, 70.8% for rubella, 24.5% for varicella.
Post-chemotherapy vaccination significantly increased immunity for rubella (81.9% vs. 64.1%, P =0.004) and varicella (35.6% vs. 16.3%, P =0.005).
Low-risk B-cell ALL patients had higher immunity rates for mumps (53.6% vs. 24.6%, P =0.0009) and rubella (81.2% vs. 66.7%, P =0.039).